Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients With Hepatocellular Carcinoma

Akihiro Saito, Masafumi Kikuchi, Yuko Matsumoto, Erina Sugawara, Gesshu Takao, Hayato Inomata, Akane Takahashi, Yuji Sato, Masaki Kumondai, Yu Sato, Toshihiro Sato, Masashi Ninomiya, Jun Inoue, Masamitsu Maekawa, Nariyasu Mano

Research output: Contribution to journalArticlepeer-review

Abstract

Background:The anticancer drug, Lenvima (lenvatinib), has severe side effects. Therapeutic drug monitoring helps ensure its efficacy and safety. Regular and optimally timed blood sampling is tough, especially when lenvatinib is self-medicated. Microsampling using the easy to handle Microsampling Wing (MSW) may help circumvent this problem. However, current lenvatinib detection methods are not sensitive enough to detect its concentrations in microsamples (<50-250 L). Thus, the aim of this study was 2-fold (1) develop an analytic method to estimate plasma lenvatinib concentrations in microsamples and (2) verify whether this method works on micro (5.6 L) blood plasma samples obtained clinically through MSW from patients with unresectable hepatocellular carcinoma (HCC).Methods:A simple, highly sensitive, and specific liquid chromatography-electrospray ionization tandem mass spectrometry method was developed. Using this novel protocol, the trough blood plasma concentration of lenvatinib was measured for both blood sampled conventionally and that using MSW. Thirty-five venous whole blood samples were obtained from 11 patients with HCC. Furthermore, the stability of lenvatinib in MSW samples during storage was evaluated.Results:The mean plasma lenvatinib concentration estimates were not significantly different between the MSW and conventional venous blood samples. CV for interday and intraday assays was low. Up to day 5, the lenvatinib concentration in the MSW samples was 85%-115% of the initial day concentration (when stored at 25°C or 4°C). The interference of endogenous matrix components in the human plasma was low.Conclusions:These results indicate that the novel mass spectrometry protocol accurately measures lenvatinib in human plasma and is reproducible. Thus, MSW could be a useful microsampling device for lenvatinib therapeutic drug monitoring in patients with HCC when used in combination with this novel liquid chromatography-electrospray ionization tandem mass spectrometry detection method.

Original languageEnglish
Pages (from-to)771-776
Number of pages6
JournalTherapeutic Drug Monitoring
Volume44
Issue number6
DOIs
Publication statusPublished - 2022 Dec 1

Keywords

  • LC/ESI-MS/MS
  • Microsampling Wing
  • lenvatinib
  • microsampling
  • therapeutic drug monitoring

Fingerprint

Dive into the research topics of 'Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients With Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this